Abstract
Objective
Concerns about off-target effects (OTEs) of genomic DNA cleavages by gene-editing enzymes have been raised, especially for OTEs that go undetected due to technical limitations. Since no explicit guidelines have been in place for risk assessment of OTEs, the regulatory authorities’ concept of an acceptable evaluation scheme for OTEs in the investigational drug application (IND) has not been clear. Here, we clarify the regulatory expectations by examining reports on OTE evaluations of leading gene-editing products that have achieved IND clearance.
Methods
We collected and analyzed the gene-editing products that have entered clinical trials by searching on ClinicalTrials.gov and EU-Clinical-Trial-Registries, and related reports for OTE evaluations from Google Scholar, PubMed, and the developers’ websites.
Results
We found a common two-step verification method used for different products at the preclinical stage. First, numerous potential off-target loci (POLs) are listed with state-of-the-art high-sensitivity detection methods and theoretical screens; Second, these OTEs are checked by amplicon sequencing of the POLs after treatment by enzymes in in vitro models close to clinical use conditions. Only the OTEs that can be detected and verified are addressed in the risk assessment in the translational phase from preclinical to clinical study.
Discussion
Here, we describe a clear scheme for risk assessment of OTEs at the key translational phase, based on the common features in protocols for gene-editing products that were cleared for use in clinical trials. This report will provide a guide for those newly attempting to conduct clinical development in this field.
Similar content being viewed by others
References
Urnov FD, Miller JC, Lee Y-L, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature. 2005;435:646–51.
Cermak T, Doyle EL, Christian M, et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 2011;39:e82.
Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816–21.
Zhang X-H, Tee LY, Wang X-G, et al. Off-target effects in CRISPR/Cas9-mediated genome engineering. Mol Ther Nucleic Acids. 2015;4:e264.
Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018;36:765–71.
FDA: Long Term Follow-Up After Administration of Human Gene Therapy Products; Guidance for Industry. 37
Bao XR, Pan Y, Lee CM, et al. Tools for experimental and computational analyses of off-target editing by programmable nucleases. Nat Protoc. 2021;16:10–26.
Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T Cells of persons infected with HIV. N Engl J Med. 2014;370:901–10.
Qasim W, Zhan H, Samarasinghe S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017. https://doi.org/10.1126/scitranslmed.aaj2013.
Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384:252–60.
Holmes MC, Reik A, Rebar EJ, et al. A potential therapy for beta-thalassemia (ST-400) and sickle cell disease (BIVV003). Biol Blood Marrow Transplant. 2018;24:S172.
Bianconi E, Piovesan A, Facchin F, et al. An estimation of the number of cells in the human body. Ann Hum Biol. 2013;40:463–71.
EMA: Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products.
ClinicalTrials.gov. https://clinicaltrials.gov/. Accessed 17 July 2022.
EU Clinical Trials Register - Update. https://www.clinicaltrialsregister.eu/.Accessed 17 July 2022.
De Dreuzy E, Heath J, Zuris JA, et al. EDIT-301: an experimental autologous cell therapy comprising Cas12a-RNP modified mPB-CD34+ Cells for the potential treatment of SCD. Blood. 2019;134:4636–4636.
Intellia Therapeutics. https://www.intelliatx.com/.Accessed 17 July 2022.
Kanter J, DiPersio JF, Leavey P, et al. Cedar trial in progress: a first in human, phase 1/2 study of the correction of a single nucleotide mutation in autologous HSCs (GPH101) to convert HbS to HbA for treating severe SCD. Blood. 2021;138:1864.
CRISPR. http://www.crisprtx.com/.Accessed 17 July 2022.
Dar H, Henderson D, Padalia Z, et al. Preclinical development of CTX120, an allogeneic CAR-T cell targeting Bcma. Blood. 2018;132:1921.
Dequeant M-L, Sagert J, Kalaitzidis D, et al. Abstract 1537: CD70 knockout: a novel approach to augment CAR-T cell function. Cancer Res. 2021;81:1537.
Cossette D, Aiyer S, Kimball C, et al. Clinical-scale production and characterization of Ntla-5001—a novel approach to manufacturing CRISPR/Cas9 engineered T cell therapies. Blood. 2021;138:3881.
Caribou Biosciences | Developing Sophisticated Allogeneic Cell Therapies. https://www.cariboubio.com/. Accessed 17 July 2022.
Vor Bio. https://www.vorbio.com/. Accessed 17 July 2022.
Maeder ML, Stefanidakis M, Wilson CJ, et al. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med. 2019;25:229–33.
Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 In vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385:493–502.
Seitzer J. NTLA-2002: CRISPR/Cas9-mediated gene knockout of KLKB1 to treat hereditary angioedema. J Allergy Clin Immunol. 2021. https://doi.org/10.1016/j.jaci.2020.12.531.
Excision Bio. https://www.excision.bio. Accessed 17 July 2022.
Perez EE, Wang J, Miller JC, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol. 2008;26:808–16.
Sangamo Therapeutics, Inc. Sangamo. https://www.sangamo.com/programs/. aAccessed 17 July 2022.
Harmatz P, Lau HA, Heldermon C, et al. Empowers: a phase 1/2 clinical trial of SB-318 ZFN-mediated in vivo human genome editing for treatment of MPS I (Hurler syndrome). Mol Genet Metab. 2019;126:S68.
Muenzer J, Prada CE, Burton B, et al. Champions: a phase 1/2 clinical trial with dose escalation of SB-913 ZFN-mediated in vivo human genome editing for treatment of MPS II (Hunter syndrome). Mol Genet Metab. 2019;126:S104.
Sangamo Therapeutics, Inc.. https://investor.sangamo.com/news-releases/news-release-details/sangamo-announces-treatment-first-patient-phase-12-clinical-0. Accessed 17 July 2022.
DiGiusto DL, Cannon PM, Holmes MC, et al. Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells. Mol Ther Method Clin Dev. 2016. https://doi.org/10.1038/mtm.2016.67.
Lattanzi A, Camarena J, Lahiri P, et al. Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Sci Transl Med. 2021. https://doi.org/10.1126/scitranslmed.abf2444.
Bae S, Park J, Kim J-S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinform Oxf Engl. 2014;30:1473–5.
Cradick TJ, Qiu P, Lee CM, et al. COSMID: a web-based tool for identifying and validating CRISPR/Cas off-target sites. Mol Ther Nucleic Acids. 2014;3:e214.
ClinicalTrials.gov. https://clinicaltrials.gov/ProvidedDocs/52/NCT01543152/Prot_000.pdf Accessed 17 July 2022.
ClinicalTrials.gov. https://clinicaltrials.gov/ProvidedDocs/65/NCT02225665/Prot_001.pdf Accessed 17 July 2022.
Clinical Trial Registration NCT01044654, Clinicaltrials.gov.https://clinicaltrials.gov/ct2/show/NCT01044654. Accessed 17 July 2022.
Clinical Trial Registration NCT02500849, Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT02500849. Accessed 17 July 2022.
Gabriel R, Lombardo A, Arens A, et al. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol. 2011;29:816–23. https://doi.org/10.1038/nbt.1948.
Kim D, Bae S, Park J, et al. Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat Method. 2015;12:237–43.
Cameron P, Fuller CK, Donohoue PD, et al. Mapping the genomic landscape of CRISPR–Cas9 cleavage. Nat Method. 2017;14:600–6.
Tsai SQ, Nguyen NT, Malagon-Lopez J, et al. CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets. Nat Method. 2017;14:607–14.
Kim D, Kim J-S. DIG-seq: a genome-wide CRISPR off-target profiling method using chromatin DNA. Genome Res. 2018;28:1894–900.
Clinical Trial Registration NCT03872479, Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT03872479. Accessed 17 July 2022.
Clinical Trial Registration NCT04601051, Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT04601051.Accessed 17 July 2022.
Clinical Trial Registration NCT04819841, Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT04819841. Accessed 17 July 2022.
Kuscu C, Arslan S, Singh R, et al. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol. 2014;32:677–83.
Tsai SQ, Zheng Z, Nguyen NT, et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. 2015;33:187–97.
Frock RL, Hu J, Meyers RM, et al. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol. 2015;33:179–86.
Wienert B, Wyman SK, Yeh CD, et al. CRISPR off-target detection with DISCOVER-seq. Nat Protoc. 2020;15:1775–99.
Yan W, Mirzazadeh R, Garnerone S, et al. BLISS is a versatile and quantitative method for genome-wide profiling of DNA double-strand breaks. Nat Commun. 2017;8:15058.
Funding
Not applicable.
Author information
Authors and Affiliations
Contributions
NY contributed to the study design, analysis, and interpretation, and he agrees to be accountable for all aspects of this work’s integrity and accuracy. AA contributed to the study design and interpretation, and he agrees to be accountable for all aspects of this work’s integrity and accuracy.
Corresponding author
Ethics declarations
Conflict of interest
Naoki Yamada is an employee of Fujifilm Pharmaceuticals U.S.A. Inc. However, the views of the author in this paper do not reflect the views of the company. Atsushi Aruga has no conflicts of interest to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Yamada, N., Aruga, A. Analysis of Off-target Effects and Risk Assessment Leading from Preclinical to Clinical Trials of Gene-edited Therapeutic Products. Ther Innov Regul Sci 57, 538–551 (2023). https://doi.org/10.1007/s43441-022-00481-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s43441-022-00481-2